RESEARCH ARTICLE

Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion

Seung Hwa Lee1*, Jeong Hoon Yang1*, Seung-Hyuk Choi1*, Taek Kyu Park1, Woo Jin Jang2, Young Bin Song1, Joo-Yong Hahn1, Jin-Ho Choi1, Hyeon-Cheol Gwon1

1 Division of Cardiology, Department of Medicine, Heart, Stroke and Vascular Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 2 Division of Cardiology, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea

☯ These authors contributed equally to this work.
* sh1214.choi@samsung.com

Abstract

Background
The duration of dual antiplatelet therapy (DAPT) after drug-eluting stent implantation in coronary chronic total occlusion (CTO) remains unclear.

Methods
We retrospectively analyzed a total of 512 patients treated with percutaneous coronary intervention (PCI) in the Samsung Medical Center CTO registry. Patients were separated into ≤ 12-month (199, 38.9%) vs. > 12 month (313, 61.1%) based on DAPT duration with aspirin and clopidogrel. The primary outcome was major adverse cardiac and cerebrovascular event (MACCE) during follow-up.

Results
Median follow-up duration was 67 (interquartile range: 51–84) months. MACCE occurred in 43 patients (21.6%) in the ≤ 12-month and 55 patients (17.6%) in the > 12-month groups. In the propensity-match population, the rate of MACCE did not differ significantly between the ≤ 12-month and > 12-month group (19.4% vs. 18.8%; hazard ratio [HR], 0.95; 95% confidential interval [CI], 0.52–1.76, p = 0.88). Moreover, moderate or severe bleeding according to BARC criteria (type 2, 3 or 5) was also similar between the ≤ 12-month and > 12-month group (2.5% vs. 1.9%; HR, 1.00; 95% CI, 0.20–4.96, p = 0.99).

Conclusion
Among patients treated with PCI for CTO, DAPT with durations of ≤ 12-month showed similar long-term clinical outcomes compared to > 12-month DAPT.
Introduction

Dual antiplatelet therapy (DAPT) with aspirin and P2Y12 receptor inhibitor is recommended for patients undergoing percutaneous coronary intervention (PCI).[1] Several former trials suggested that there is no net clinical benefit of DAPT beyond 12 months after drug-eluting stent (DES) implantation in terms of ischemic and bleeding event, although recent large randomized trials report benefits associated with DAPT over 12 months, which were accompanied by an increased number of bleeding events.[2–6] In addition, clinical presentation which associated with unstable plaque or plaque rupture may benefit with long-duration DAPT although their prevalence is not negligible in stable patients.[7] Therefore, long-duration DAPT is difficult to apply in all patients, and multiple factors have to be integrated: type of stent, clinical presentation, type of dual antiplatelet therapy, coronary lesion complexity, and patient compliance.[8]

The optimal duration of DAPT may differ in patients with coronary chronic total occlusion (CTO) because such patients are at higher risk of ischemic events.[9] Although it has become more common to undergo PCI to treat CTO and the success rates of such treatment have increased, the optimal duration of DAPT after DES implantation in patients with CTO remains unclear.[10–13] Therefore, the aim of the present study was to compare long-term clinical outcomes between patients with CTO who were treated with prolonged DAPT and those treated for up to 12 month after PCI with DES.

Methods

Study population

This study was retrospective analysis with selected CTO patients from prospective registry. Between March 2003 and February 2012, 2,024 consecutive patients were enrolled in the Samsung Medical Center CTO registry. Clinical, laboratory and outcome data were collected by a trained study coordinator using a standardized case report form and protocol. If necessary, additional information was documented by contacting the principal investigators and/or by review of hospital records. The Institutional Review Board of Samsung Medical Center approved the study protocol and waived the requirement for informed consent. The inclusion criteria for the registry were: 1) patients treated for PCI with DES for CTO, 2) at least one CTO detected on diagnostic coronary angiography, and 3) symptomatic angina and/or a positive functional ischemia study. Exclusion criteria included: 1) failed PCI, 2) medical therapy alone without PCI, 3) previous coronary artery bypass graft surgery, 4) history of cardiogenic shock or cardiopulmonary resuscitation, 5) ST-segment elevation myocardial infarction (MI) during the preceding 48 hours, and 6) use of warfarin or antiplatelet agent, other than aspirin and clopidogrel. Patients with major adverse cardiac and cerebrovascular events (MACCE) during the first 12 month excluded.

Definitions and outcomes

A CTO lesion was defined as the obstruction of a native coronary artery with thrombolysis in myocardial infarction (TIMI) flow grade 0 with an estimated duration longer than three months.[3] Duration was estimated based on the interval from the last episode of acute coronary syndrome (ACS) or in patients with no history of ACS, from the first episode of exertional angina consistent with the location of the occlusion or previous coronary angiogram. Successful PCI was defined as final residual stenosis less than 20% of the vessel diameter, with TIMI flow grade ≥ 2 after revascularization, as assessed by visual estimation on angiography.
The primary outcome was the MACCE during follow-up. The secondary outcomes were each of MACCE, cardiac death, or moderate or severe bleeding during the same period (assessed according to the Bleeding Academic Research Consortium [BARC] criteria).[14] MI was defined as recurrent symptoms with new electrocardiographic changes compatible with MI or cardiac markers at least twice the upper limit of normal.[15] Periprocedural enzyme elevation was not included in this definition of MI. The incidence of bleeding was also evaluated according to Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) and TIMI criteria.

Statistical analysis

Comparisons for continuous variables were made using t-tests or the Wilcoxon rank-sum test when applicable, and results are presented as mean ± standard deviation or median with interquartile ranges. Differences between groups were evaluated using chi-square or Fisher’s exact tests for categorical data. We used landmark analysis in this study, and we defined landmark of DAPT discontinuation at 12 month. Survival curves were constructed using Kaplan-Meier estimates and compared with the log-rank test. Univariable and multivariable Cox proportional hazard regression models were used to compare reductions in the risks of outcomes. Variables associated with MACCE (acute coronary syndrome, location of CTO, multivessel disease and newer generation stent) were included in multiple cox-regression analyses to search for independent predictors. To reduce treatment-selection bias and potential confounding factors, we performed rigorous adjustments for the baseline and lesion characteristics of the patients using their propensity scores, which we estimated using multiple logistic-regression analyses. Model discrimination was assessed with c-statistics, and model calibration was assessed with Hosmer-Lemeshow statistics (P = 0.22). An absolute standardized difference < 10% for the measured covariate suggested an appropriate balance between the groups. The covariate balance achieved by matching was assessed by calculating the absolute standardized differences in covariates between the ≤ 12-month and > 12-month groups. An absolute standardized mean difference of <10% for the measured covariate suggests appropriate balance between groups. In the propensity score-matched population, continuous variables were compared with a paired t-test, as appropriate, and categorical variables were compared with the McNemar’s test of symmetry, as appropriate. The reduction in the risk of outcome was compared using the stratified Cox regression model. Statistical analyses were performed with SPSS 20.0.0 (IBM Corp. Armonk, NY, USA). All tests were two-tailed and p < 0.05 was considered statistically significant.

Results

Baseline and procedural characteristics

The patient flow of the study is shown in Fig 1. The baseline characteristics of the CTO patients in the ≤ 12-month (N = 199), and > 12-month (N = 313) DAPT groups are described in Table 1.

The median duration of DAPT was 292 days (IQR, 184–363 days) in the ≤ 12-month group. Compared with patients in the > 12-month DAPT group, those in the ≤ 12-month group were younger and had a lower incidence of chronic kidney disease, history of PCI, and history of stroke. Fig 2 shows the distribution of DAPT duration.

Table 2 shows the lesion and procedural characteristics.

The > 12-month group showed higher rate of newer generation stents, longer total stent length, and smaller minimal stent diameter compared to ≤ 12-month DAPT. The types of stents were described in S1 Table. After performing propensity-score matching for the entire
population, a total of 185 pairs of matched data set were generated by 1:1 individual matching without replacement using propensity score. There were no significant differences in baseline clinical or lesion characteristics between the two groups for the propensity-matched subjects (Tables 1 and 2).

Table 1. Baseline characteristics according to duration of dual antiplatelet therapy.

| Variables               | Total population | Propensity-matched population | p-value | Standardized mean difference | Total population | Propensity-matched population | Standardized mean difference |
|-------------------------|------------------|--------------------------------|---------|-----------------------------|------------------|--------------------------------|-----------------------------|
| Age                     | 59.2 (±10.50)    | 61.4 (±11.35)                 | 0.03    | -20.58                      | 59.3 (±10.54)    | 59.4 (±11.3)                  | -0.72                       |
| Male                    | 158 (79.4)       | 257 (82.1)                    | 0.45    | 6.69                        | 146 (78.9)       | 144 (77.8)                   | 2.67                        |
| Medical history         |                  |                                |         |                             |                  |                                |                             |
| Diabetes                | 73 (36.7)        | 134 (42.8)                    | 0.17    | -12.68                      | 67 (36.2)        | 73 (39.5)                    | -6.71                       |
| Hypertension            | 109 (54.8)       | 193 (61.7)                    | 0.12    | -13.8                       | 100 (54.1)       | 101 (54.6)                   | -1.08                       |
| Chronic kidney disease  | 5 (2.5)          | 26 (8.3)                      | 0.007   | -36.93                      | 5 (2.7)          | 5 (2.7)                      | 0                           |
| Smoking                 | 70 (35.2)        | 101 (32.3)                    | 0.50    | 6.07                        | 66 (35.7)        | 68 (36.8)                    | -2.26                       |
| Dyslipidemia            | 71 (35.7)        | 112 (35.8)                    | 0.98    | -0.22                       | 66 (35.7)        | 71 (38.4)                    | -5.63                       |
| History of MI           | 32 (16.1)        | 61 (19.5)                     | 0.33    | 9.26                        | 30 (16.2)        | 29 (15.7)                    | 1.47                        |
| History of PCI          | 17 (8.5)         | 53 (16.9)                     | 0.007   | -29.94                      | 17 (9.2)         | 17 (9.2)                     | 0                           |
| History of stroke       | 5 (2.5)          | 27 (8.6)                      | 0.005   | -38.96                      | 5 (2.7)          | 4 (2.2)                      | 3.45                        |
| Left ventricular ejection fraction | 59.4 (±10.21) | 58.0 (±11.07) | 0.15 | 13.89 | 58.5 (±10.0) | 58.7 (±10.87) | 7.17 |
| Acute coronary syndrome | 48 (24.1)        | 79 (25.2)                     | 0.78    | -2.61                       | 46 (24.9)        | 40 (21.6)                    | 7.56                        |
| SYNTAX score            | 19.4 (±8.37)     | 20.4 (±9.03)                  | 0.11    | -11.47                      | 19.6 (±8.49)     | 19.5 (±8.47)                 | 0.41                        |

Data are presented as mean ± standard deviation or n (%).

DAPT, dual antiplatelet therapy; MI, myocardial infarction; SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery.

https://doi.org/10.1371/journal.pone.0176737.t001
Clinical outcomes

The median follow-up duration was 64 months (IQR 48 to 82) for the entire population. Table 3 shows clinical outcomes in the ≤ 12-month and > 12-month DAPT groups in the entire population. There was no significant difference between the two groups in rate of MACCE (21.6% vs. 17.6%; adjusted hazard ratio [HR] 1.27, 95% confidence interval [CI] 0.83–1.94, p = 0.26) in multivariate analysis (Table 3, Fig 3).

Moreover, moderate or severe bleeding according to BARC criteria (type 2, 3 or 5) (2.2% vs. 3.5%; HR, 1.14; 95% CI, 0.32–4.07, p = 0.85) was also similar between two groups. After propensity-matching, either the rate of MACCE (22.2% vs. 16.8%; HR, 1.32; 95% CI, 0.81–

Table 2. Lesion and procedural characteristics according to duration of dual antiplatelet therapy.

| Variables                        | Total population | Propensity-matched population |
|----------------------------------|------------------|-------------------------------|
|                                  | ≤ 12-month DAPT   | > 12-month DAPT                | p-value | Standardized mean difference | ≤ 12-month DAPT   | > 12-month DAPT                | Standardized mean difference |
| CTO lesion                       | (N = 199)        | (N = 313)                     |         |                             | (N = 185)        | (N = 185)                     |                             |
| Left anterior descending artery  | 90 (45.2)        | 147 (47.0)                    | 0.70    | -3.48                        | 83 (44.9)        | 81 (43.8)                     | 2.17                         |
| Left circumflex artery           | 52 (26.1)        | 80 (25.6)                     | 0.89    | 1.3                          | 49 (26.5)        | 51 (27.6)                     | -2.45                        |
| Right coronary artery            | 82 (41.2)        | 141 (45.0)                    | 0.39    | -7.79                        | 78 (42.2)        | 78 (42.2)                     | 0                            |
| Multivessel disease              | 134 (67.3)       | 205 (65.5)                    | 0.67    | 3.92                         | 127 (68.7)       | 121 (65.4)                    | 6.9                           |
| CTO at proximal to mid           | 152 (76.4)       | 240 (76.7)                    | 0.04    | -0.69                        | 141 (76.2)       | 134 (72.4)                    | 8.89                         |
| Multiple CTO                     | 24 (12.1)        | 54 (17.3)                     | 0.11    | -15.9                        | 24 (13.0)        | 25 (13.5)                     | -1.66                        |
| New generation stent             | 66 (33.2)        | 168 (53.7)                    | < 0.001 | -43.45                       | 64 (34.6)        | 72 (38.9)                     | -9.16                        |
| Total stent number               | 1.73 (±0.87)     | 1.85 (±0.91)                  | 0.13    | -14.32                       | 1.76 (±0.87)     | 1.76 (±0.90)                  | 0                             |
| Total stent length               | 35.3 (±15.94)    | 38.5 (±18.90)                 | 0.05    | -20.22                       | 35.8 (±16.16)    | 35.9 (±18.86)                 | -0.75                        |
| Minimum stent diameter           | 3.06 (±0.43)     | 2.91 (±0.42)                  | < 0.001 | 16.5                         | 3.06 (±0.43)     | 3.07 (±1.60)                  | -2.21                        |

Data are presented as mean ± standard deviation or n (%).

DAPT, dual antiplatelet therapy; CTO, chronic total occlusion.

https://doi.org/10.1371/journal.pone.0176737.t002
Table 3. Clinical outcomes of ≤ 12-month DAPT vs > 12-month DAPT in the crude population.

|                  | ≤ 12-month DAPT | > 12-month DAPT | Unadjusted HR (95% CI) | p-value | Multivariate analysis‡ | Adjusted HR (95% CI) | p-value |
|------------------|-----------------|-----------------|------------------------|---------|------------------------|----------------------|---------|
| MACCE            | 43 (21.6)       | 55 (17.6)       | 1.05 (0.70–1.56)       | 0.83    | 1.27 (0.83–1.94)       | 0.26                 |
| Stent thrombosis*| 4 (2.0)         | 5 (1.6)         | 1.08 (0.29–4.03)       | 0.91    | 0.96 (0.90–7.00)       | 0.53                 |
| All cause death  | 13 (6.5)        | 16 (5.1)        | 1.18 (0.56–2.45)       | 0.67    | 1.60 (0.73–3.53)       | 0.24                 |
| Cardiac death    | 6 (3.0)         | 5 (1.6)         | 1.67 (051–5.50)        | 0.40    | 2.12 (0.60–7.56)       | 0.25                 |
| Myocardial infarction | 3 (1.5)  | 10 (3.2)        | 0.41 (0.11–1.49)       | 0.18    | 0.54 (0.14–2.12)       | 0.38                 |
| Stroke           | 2 (1.0)         | 4 (1.3)         | 0.72 (0.13–3.92)       | 0.33    | 1.13 (0.19–6.57)       | 0.89                 |
| Repeat revascularization | 29 (14.6) | 36 (11.5)      | 1.05 (0.64–1.71)       | 0.72    | 1.21 (0.72–2.03)       | 0.47                 |
| BARC type 2, 3 or 5 | 4 (2.0)     | 11 (3.5)        | 0.52 (0.17–1.64)       | 0.27    | 0.75 (0.82–2.77)       | 0.75                 |
| GUSTO severe or moderate | 1 (0.5) | 8 (2.6)         | 0.17 (0.02–1.40)       | 0.10    | 0.26 (0.03–2.23)       | 0.22                 |
| TIMI major or minor | 1 (0.5)        | 7 (2.2)         | 0.20 (0.02–1.61)       | 0.13    | 0.31 (0.04–2.67)       | 0.29                 |

Data are presented as n (%).
DAPT, dual antiplatelet therapy; BARC, Bleeding Academic Research Consortium; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries; TIMI, Thrombolysis in Myocardial Infarction; CI, confidence interval; HR, hazard ratio
‡ Covariates include age, diabetes, hypertension, chronic kidney disease, history of PCI, history of stroke, newer generation stent, total stent length, and minimum stent diameter
* Stent thrombosis includes definite or probable stent thrombosis

https://doi.org/10.1371/journal.pone.0176737.t003

Fig 3. Kaplan-Meier curves for MACCE and moderate to severe bleeding between ≤ 12-month (red line) and >12-month DAPT (blue line) groups in the entire population. (A) curves for MACCE and (B) curves for moderate to severe bleeding (BARC 2, 3 or 5).

https://doi.org/10.1371/journal.pone.0176737.g003
2.18; p = 0.26) or moderate or severe bleeding (1.6% vs. 2.2%; HR, 0.76; 95% CI, 0.17–3.44; p = 0.72) showed no differences (Table 4, Fig 4).

There were no significant interactions between DAPT duration and baseline, lesion and procedural characteristics of interest with respect to the MACCE, as described in the hazard-ratio plots in Fig 5.

Discussion

In the present study, we investigated clinical outcomes according to the duration of DAPT in patients treated PCI for CTO. Among patients who were event-free at 12 months, no significant differences were observed in the incidence of MACCE or moderate to severe bleeding between patients with CTO taking > 12-month DAPT and those changed to single antiplatelet therapy in 12 month.

Among patients receiving DES for non-ACS indication, current 2016 ACC/AHA guidelines and 2014 ESC/EACTS Guidelines on myocardial revascularization recommend the duration of DAPT for 6 months after DES implantation.[1, 16] Physicians tend to prefer prolonged DAPT in high-risk patients. Gilard and Morice explained that there is a possibility that only high-risk patients with conditions such as prior MI, multiple stents, left main stent, prior stent thrombosis, diabetes or diffuse coronary artery disease benefit from long-duration DAPT.[8] Generally, patients with CTO tend to be older and show higher incidences of comorbidities such as diabetes, hypertension or stroke.[9] Furthermore, coronary arteries with CTO show increased atherosclerotic burden, calcification, and longer lesions which contributes to higher SYNTAX score. Thus, it could be anticipated that patients with CTO are at higher ischemic risk and therefore benefit from longer duration of DAPT because patients treated with PCI for CTO have longer stent lengths or multiple stents.[9, 17] However, to date, limited data are available regarding the relationship between duration of DAPT and clinical outcomes in patients with CTO. The EuroCTO club reported good results after DAPT of 12 months in patients treated with sirolimus-eluting stents with non-erodible matrix and 6 months in patients treated with sirolimus-eluting stents with biodegradable polymers.[12, 18, 19] Most clinical trials of DAPT excluded patients with CTO, and even in several trials that included patients with CTO, additional subgroup analysis was not performed to investigate the clinical

Table 4. Clinical outcomes of ≤ 12-month DAPT vs > 12-month DAPT in the propensity-matched population.

|                     | ≤ 12-month DAPT | > 12-month DAPT | Adjusted HR (95% CI) | p-value |
|---------------------|-----------------|-----------------|----------------------|---------|
| MACCE               | 41 (22.2)       | 31 (16.8)       | 1.32 (0.81–2.18)    | 0.26    |
| Stent thrombosis*   | 4 (2.2)         | 4 (2.2)         | 0.99 (0.30–3.26)    | 0.98    |
| All cause death     | 11 (5.9)        | 7 (3.8)         | 1.58 (0.60–4.17)    | 0.35    |
| Cardiac death       | 5 (2.7)         | 3 (1.6)         | 1.67 (0.40–7.07)    | 0.48    |
| MI                  | 3 (1.6)         | 6 (3.2)         | 0.50 (0.15–1.68)    | 0.30    |
| Stroke              | 2 (1.1)         | 0               |                      |         |
| Repeat revascularization | 29 (15.7)   | 24 (13.0)       | 1.22 (0.69–2.13)    | 0.50    |
| BARC type 2, 3 or 5 | 3 (1.6)         | 4 (2.2)         | 0.76 (0.17–3.44)    | 0.72    |
| GUSTO severe or moderate | 1 (0.5)    | 4 (2.2)         | 0.25 (0.03–2.30)    | 0.22    |
| TIMI major or minor | 1 (0.5)         | 3 (1.6)         | 0.34 (0.03–3.30)    | 0.35    |

Values are n (%).
DAPT, dual antiplatelet therapy; BARC, Bleeding Academic Research Consortium; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries; TIMI, Thrombolysis in Myocardial Infarction; CI, confidence interval; HR, hazard ratio

* Stent thrombosis includes definite or probable stent thrombosis

https://doi.org/10.1371/journal.pone.0176737.t004
Fig 4. Kaplan-Meier curves for MACCE and moderate to severe bleeding between ≤ 12-month (red line) and >12-month DAPT (blue line) groups in the propensity-matched population. (A) curves for MACCE and (B) curves for moderate to severe bleeding (BARC 2, 3 or 5).

https://doi.org/10.1371/journal.pone.0176737.g004

Fig 5. Comparison of MACCE in the subgroups. 95%CI, 95% confidence interval; HR, hazard ratio; CTO, chronic total occlusion.

https://doi.org/10.1371/journal.pone.0176737.g005
impact of prolonged DAPT in CTO patients.\cite{4, 20–22} Recently published data showed that longer duration DAPT was not associated with improved clinical outcomes in the CTO patients, although other subset of complex PCI, such as longer stent length, bifurcation stenting or number of stents more than three, showed better clinical outcomes.\cite{23} To the best of our knowledge, this is the first study performed a direct comparison of DAPT durations in patients with CTO-PCI.

Several previous studies suggest that there is no clinical benefit of longer duration DAPT.\cite{21, 24} A recent meta-analysis argued that the risk/benefit ratio between stopping or continuing DAPT after an initially recommended period should be carefully individualized considering the trade-off between future risk of ischemia and bleeding.\cite{25} The results of the present study are informative regarding the individualized DAPT.

In this study, we observed no differences in clinical outcomes indicating ischemic events between the \(\leq 12\)-month and >12-month DAPT groups. There are several possible explanations for these results. First, patients with CTO present more often with stable coronary disease than ACS.\cite{8} As a result, the frequency of thrombotic ischemic events, such as stent thrombosis might not differ, despite high lesion complexity and longer lesions. Patients with ST-segment elevation MI were excluded from this study, and among patients without MI, composite end points show no significant difference between prolonged DAPT and 12-months DAPT.\cite{26} Therefore, the characteristics of patients with CTO may explain the similar rates of MACCE and stent thrombosis between groups. Second, we excluded patients with a history of PCI for more precise comparisons between groups. Study populations of previous studies that favored longer duration DAPT showed a higher incidence of prior PCI or MI than the present study.\cite{5, 6}

The most concerning outcome of prolonged DAPT is increased bleeding risk.\cite{27} In this study, numerically higher rates of bleeding events were observed in the >12-month group compared to \(\leq 12\)-month group, but the differences between the two groups were not statistically significant. Larger registry data or randomized trial is needed to evaluate clinical relevance.

Our study has several limitations. First, it was not a randomized trial: the selection of treatment was influenced by patient characteristics and patient and physician preferences. To address this limitation, we conducted propensity score-matched analysis to adjust for differences in patient characteristics. However, a strong possibility remains that other unmeasured or undocumented factors may have confounded the relationship between treatment strategies and outcomes, despite extensive adjustment for baseline risk factors. Second, the number of subjects was small as we targeted patients with successful PCI only. Third, the DAPT regimen consisted of aspirin and clopidogrel. During the study period, P2Y12 receptor inhibitors such as prasugrel or ticagrelor were not available in Korea. Fourth, the duration of DAPT is at the discretion of the physician. Finally, due to limitations of landmark analysis, there may be a possibility of omission of time-to-event distribution prior to landmark time and data-driven results. Despite these limitations, our study provides data for long-term follow-up and offers direct comparisons according to the duration of DAPT.

**Conclusion**

In patients treated with PCI for CTO, the \(\leq 12\)-month DAPT associated with similar rates of MACCE and moderate to severe bleeding compared to the >12-month DAPT. Larger randomized controlled trials are needed to validate our results.

**Supporting information**

S1 Table. Types of stents. (DOCX)
Author Contributions

Conceptualization: SHL.
Data curation: JHY WJJ.
Formal analysis: SHL JHY.
Investigation: SHL JHY SHC TKP WJJ YBS JYH JHC HCG.
Methodology: SHL JHY.
Project administration: JHY SHC.
Supervision: JHY SHC.
Validation: SHL JHY.
Visualization: SHL.
Writing – original draft: SHL.
Writing – review & editing: JHY SHC.

References

1. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. J Am Coll Cardiol. 2016; 68: 1082–1115. https://doi.org/10.1016/j.jacc.2015.03.513 PMID: 27036918

2. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial. Circulation. 2012; 125: 2015–2026. https://doi.org/10.1161/CIRCULATIONAHA.111.071589 PMID: 22438530

3. Gwon H-C, Hahn J-Y, Park KW, Song Y Bin, Chae I-H, Lim D-S, et al. Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study. Circulation. 2012; 125: 505–513. https://doi.org/10.1161/CIRCULATIONAHA.111.059022 PMID: 22179532

4. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013; 310: 2510–22. https://doi.org/10.1001/jama.2013.282183 PMID: 24177257

5. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med. 2014; 371: 2155–2166. https://doi.org/10.1056/NEJMoa1409312 PMID: 25399658

6. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015; 372: 1791–1800. https://doi.org/10.1056/NEJMoa1500857 PMID: 25773268

7. Iannaccone M, Quadri G, Taha S, D’Ascenzo F, Montefusco A, Omede’ P, et al. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. Eur Hear J—Cardiovasc Imaging. 2015; jev283.

8. Gilard M, Morice MC. Double Antiplatelet Therapy Duration. J Am Coll Cardiol. 2015; 65: 2222–2224 https://doi.org/10.1016/j.jacc.2015.03.541 PMID: 25998667

9. Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, et al. Current Perspectives on Coronary Chronic Total OcclusionsThe Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol. 2012; 59: 991–997. https://doi.org/10.1016/j.jacc.2011.12.007 PMID: 22402070

10. Patel MR, Marso SP, Dai D, Anstrom KJ, Shunk KA, Curtus JP, et al. Comparative Effectiveness of Drug-Eluting Versus Bare-Metal Stents in Elderly Patients Undergoing Revascularization of Chronic Total Coronary OcclusionsResults From the National Cardiovascular Data Registry, 2005–2008. JACC Cardiovasc Interv. 2012; 5: 1054–1061. https://doi.org/10.1016/j.jcin.2012.05.017 PMID: 23078736

11. Tamburino C, Capranzano P, Capodanno D, Dangas G, Zimarino M, Bass TA, et al. Percutaneous recanalization of chronic total occlusions: Wherein lies the body of proof? Am Heart J. 2013; 165: 133–142. https://doi.org/10.1016/j.ahj.2012.10.017 PMID: 23351815
12. Sianos G, Werner GS, Galassi AR, Papakakis MI, Escaned J, Hildick-Smith D, et al. Recanalisation of chronic total coronary occlusions: 2012 consensus document from the EuroCTO club. EuroIntervention. 2012; 8: 139–145. https://doi.org/10.4244/EIJV8I1A21 PMID: 22580257

13. Lee SH, Yang JH, Choi S-H, Song Y Bin, Hahn J-Y, Choi J-H, et al. Long-Term Clinical Outcomes of Medical Therapy for Coronary Chronic Total Occlusions in Elderly Patients (>75 Years). Circ J. 2015; 79: 1780–1786. https://doi.org/10.1253/circj.CJ-15-0041 PMID: 26017064

14. Mehran R, Rao SV., Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the the bleeding academic research consortium. Circulation. 2011; 123: 2736–2747. https://doi.org/10.1161/CIRCULATIONAHA.110.09449 PMID: 21670242

15. Lee KH, Jeong MH, Kim HM, Ahn Y, Kim JH, Chae SC, et al. Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol. J Am Coll Cardiol. Elsevier Inc.; 2011; 58: 1664–71.

16. Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) * Developed with the special contribution. Eur Heart J. 2014; 35: 2541–2619. https://doi.org/10.1093/eurheartj/ehu278 PMID: 25173339

17. Stone GW, Kandzari DE, Mehran R, Colombo A, Schwartz RS, Bailey S, et al. Percutaneous Recanalization of Chronically Occluded Coronary Arteries A Consensus Document: Part I. Circulation. 2005; 112: 2364–2372. https://doi.org/10.1161/CIRCULATIONAHA.104.481283 PMID: 16216980

18. Galassi AR, Tomasello SD, Costanzo L, Campisano MB, Barrano G, Tamburino C. Long-term clinical and angiographic results of sirolimus-eluting stent in complex coronary chronic total occlusion revascularization: The SECTOR registry. J Interv Cardiol. 2011; 24: 426–436. https://doi.org/10.1111/j.1540-8183.2011.00648.x PMID: 22004600

19. Reifart N, Hauptmann K-E, Rabe A, Enayat D, Giokoglu K. Short and long term comparison (24 months) of an alternative sirolimus-coated stent with bioabsorbable polymer and a bare metal stent of similar design in chronic coronary occlusions: the CORACTO trial. EuroIntervention. 2010; 6: 356–360. https://doi.org/10.4244/EIJV6I3A59 PMID: 20884414

20. Schulz-Schupke S, Byrne RA, ten Berg JM, Neumann F-J, Han Y, Adriaenssens T, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015; 36: 1252–1263. https://doi.org/10.1093/eurheartj/ehu523 PMID: 25616646

21. Lee CW, Ahn J-M, Park D-W, Kang S-J, Lee S-W, Kim Y-H, et al. Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Randomized, Controlled Trial. Circulation. 2014; 129: 304–312. https://doi.org/10.1161/CIRCULATIONAHA.113.003303 PMID: 24097439

22. Abo-Salem E, Alsidawi S, Jamali H, Effat M, Helmy T. Optimal duration of dual antiplatelet therapy after drug eluting stents: Meta-analysis of randomized trials. Cardiovasc Ther. 2015; 33: 253–263. https://doi.org/10.1111/1755-5922.12137 PMID: 26010419

23. Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, et al. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. J Am Coll Cardiol. 2016; 68: 1851–1864. https://doi.org/10.1016/j.jacc.2015.07.060 PMID: 27595509

24. Costa F, Vranckx P, Leonard R, Moscarella E, Ando G, Calabro P, et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After. Eur Heart J. 2015; 36: 1242–1251. https://doi.org/10.1093/eurheartj/ehv038 PMID: 25718355

25. Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, et al. Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol. 2015; 65: 1298–1310. https://doi.org/10.1016/j.jacc.2015.01.039 PMID: 25681754

26. Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, et al. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy after PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015; 65.

27. Ikegami Y, Kohsaka S, Miyata H, Ueda I, Fuse J, Sakamoto M, et al. Outcomes of Percutaneous Coronary Intervention Performed With or Without Preprocedural Dual Antiplatelet Therapy. Circ J. 2015; 79: 2598–2607. https://doi.org/10.1253/circj.CJ-15-0484 PMID: 26447105